DISCOUNT OPTIONSSCHEIN - MODERNA | Market Closed - Deutsche Boerse AG 02:02:15 2024-06-17 pm EDT | ||
| 2.93 EUR | +0.69% |
|
| Current month | +1.03% | ||
| 1 month | +5.40% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-06-17 | 2.93 | +0.69% |
| 24-06-14 | 2.91 | -4.28% |
| 24-06-13 | 3.04 | -0.65% |
| 24-06-12 | 3.06 | +0.33% |
| 24-06-11 | 3.05 | 0.00% |
Delayed Quote Deutsche Boerse AG
Last update June 17, 2024 at 02:02 pm EDT
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | 
Vontobel
|
| WKN | VU9HB1 |
| ISIN | DE000VU9HB18 |
| Date issued | 2023-07-05 |
| Strike | 80 $ |
| Maturity | 2024-12-20 (186 Days) |
| Parity | 10 : 1 |
| Emission price | 2.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.2 € |
|---|---|
| Lowest since issue | 0.82 € |
| Spread | 0.01 € |
| Spread % | 0.34% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
137.9
USD
Average target price
145.2
USD
Spread / Average Target
+5.27%
- Stock Market
- Certificates
- Certificat
